A statistically significant association with a p-value of 0.024 was observed between the PD-L1 score and tumor-infiltrating immune cells, suggesting that frequent PD-L1 expression in tumors with significant TILs may be useful in identifying patients who may benefit from anti-PD-1/PD-L1 therapy. The gene discussed is PDCD1; the disease is neoplasm.